New drug PN-881 enters first human safety tests
NCT ID NCT07153146
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new drug, PN-881, in 142 healthy adults to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo as a single dose or multiple doses. The study is not designed to treat any disease but to gather important safety information for future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PN-881
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nucleus Network
RECRUITINGMelbourne, Victoria, 3004, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Avocado at breakfast: a secret weapon for blood sugar and fullness?
- New drug BIIB115 aims to build on gene therapy for spinal muscular atrophy
- Melt-in-Mouth migraine pill could make dosing easier
- Scientists test how body weight influences a new drug's absorption
- First human test of BIIB144 begins: safety first
- Antifungal drug may alter levels of experimental cancer pill